Blueprint Medicines Corp (BPMC)

107.02 +12.16 (+12.82%) USD  |  NASDAQ  |  May 02, 16:00
107.02 0.00 (0.00%) After-Hours: 19:10
More

Blueprint Medicines Research and Development Expense (Quarterly): 97.54M for Dec. 31, 2023

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2014. Upgrade now.
Date Value
December 31, 2023 97.54M
September 30, 2023 110.25M
June 30, 2023 110.06M
March 31, 2023 112.07M
December 31, 2022 117.84M
September 30, 2022 127.98M
June 30, 2022 128.47M
March 31, 2022 103.13M
December 31, 2021 356.88M
September 30, 2021 84.42M
June 30, 2021 80.03M
March 31, 2021 79.71M
December 31, 2020 77.40M
September 30, 2020 74.23M
June 30, 2020 91.08M
March 31, 2020 84.15M
December 31, 2019 88.65M
September 30, 2019 81.45M
June 30, 2019 87.10M
March 31, 2019 74.25M
Date Value
December 31, 2018 70.53M
September 30, 2018 64.56M
June 30, 2018 58.57M
March 31, 2018 49.95M
December 31, 2017 43.63M
September 30, 2017 39.30M
June 30, 2017 33.27M
March 31, 2017 28.49M
December 31, 2016 24.07M
September 30, 2016 18.15M
June 30, 2016 21.27M
March 31, 2016 17.64M
December 31, 2015 16.43M
September 30, 2015 11.68M
June 30, 2015 11.24M
March 31, 2015 9.232M
December 31, 2014 11.33M
September 30, 2014 8.368M
June 30, 2014 6.762M
March 31, 2014 5.381M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

74.23M
Minimum
Sep 2020
356.88M
Maximum
Dec 2021
110.13M
Average
91.08M
Median
Jun 2020

Research and Development Expense (Quarterly) Benchmarks

Alnylam Pharmaceuticals Inc 272.14M
Apellis Pharmaceuticals Inc 69.28M
Ionis Pharmaceuticals Inc 256.56M
Madrigal Pharmaceuticals Inc 70.64M
Sarepta Therapeutics Inc 195.52M